Overview of Ausentron

Property	Description
Active ingredient	Clomipramine Hydrochloride
Form	Capsules, Tablets, Intravenous preparations
Pharmacological class	Tricyclic Antidepressant (TCA)
Common purpose	Supporting mental balance and mood regulation
Origin	Synthetic compound (Dibenzazepine-derivative)

What Type of Medicine is Ausentron?

Ausentron is a prescription-only pharmaceutical preparation whose active ingredient is Clomipramine Hydrochloride. This medicine is classified as a Tricyclic Antidepressant (TCA), belonging to the dibenzazepine chemical class. This compound is a member of an established drug family known for its use in neurological applications. This classification reflects its long-standing recognition within clinical practice for systemic treatment.

As a synthetic compound, Ausentron is manufactured as a single-ingredient product, confirming that its pharmacological action relies on Clomipramine. It is primarily provided for oral administration in forms such as capsules or tablets, though intravenous preparations also exist for clinical use. Its identification as a TCA confirms its function as a systemic drug designed to influence neurological processes within the brain.

Composition and General Purpose of Clomipramine Hydrochloride

The core component of Ausentron is the Clomipramine Hydrochloride molecule, a tertiary amine that functions as a potent non-selective monoamine reuptake inhibitor.

The general purpose of this medicine is to modulate neurotransmission to support mental balance. It achieves this by increasing the levels of chemical messengers—specifically serotonin (5-HT) and norepinephrine (NE)—in the brain's synaptic spaces. The mechanism involves the inhibition of serotonin reuptake. Pharmacological properties indicate a robust mechanism for stabilizing mood. By regulating these neurotransmitters, the medicine supports the management of mental health conditions by improving emotional regulation and tempering the neuronal circuits associated with repetitive mental processes.

Regulatory References

NIH Bookshelf - Clomipramine

What side effects are possible with Ausentron?

Possible side effects and safety information

The safety profile of Ausentron (Clomipramine Hydrochloride) is officially documented across several categories, reflecting adverse reactions classified by frequency and system involvement, as reported by regulatory authorities.

Adverse Reaction Frequency and System Involvement

Adverse reactions are organized based on their expected frequency of occurrence, primarily affecting the Nervous System and exhibiting anticholinergic properties.

Very Common (ge 1/10): Dry mouth, constipation, dizziness, tremor, somnolence, fatigue, and sexual dysfunction are officially listed.
Common (ge 1/100 to <1/10): Reactions include nausea, vomiting, increased appetite, anxiety, agitation, sinus tachycardia, and urinary retention.
Uncommon to Very Rare: Less frequent but serious reactions include convulsions (seizures), arrhythmias, and very rare syndromes such as Neuroleptic Malignant Syndrome (NMS).

Serious Adverse Reactions and Safety Constraints

The regulatory label includes warnings for serious adverse reactions. The risk of Suicidal Ideation and Behavior is explicitly noted, particularly in adolescents and young adults during the initial stages of treatment or following dose adjustments. Serious Cardiac Toxicity, including arrhythmias and QTc prolongation, is documented as a safety concern.

Use of Ausentron is contraindicated in individuals with a recent myocardial infarction or those currently taking Monoamine Oxidase Inhibitors (MAOIs). Older adults are noted to be at a higher risk for adverse effects, specifically confusion, hallucinations, and postural hypotension.

Overdose and Emergency Response

Suspected overdose of Ausentron (Clomipramine Hydrochloride) requires immediate emergency medical attention due to the severe, potentially fatal outcomes documented in official regulatory labeling. Overdose frequently presents with signs of severe Central Nervous System (CNS) toxicity, including profound drowsiness, stupor, coma, or convulsions. Other acute neurological effects can involve agitation, muscular rigidity, and severe confusion. Anticholinergic signs such as mydriasis and oliguria may also be present.

The most critical regulatory concern involves the cardiovascular system, with documented risks including severe hypotension, tachycardia, QTc prolongation, and life-threatening arrhythmias, such as Torsades de pointes, which can lead to cardiac arrest. Respiratory depression and the development of Serotonin Syndrome are also listed as severe or life-threatening manifestations.

Official government guidance mandates that treatment is solely symptomatic and supportive, as no specific antidote is known. Procedures may include gastric lavage and activated charcoal to reduce systemic absorption. Continuous monitoring, particularly of cardiac function, blood gases, and electrolytes, is required for at least 72 hours following the event, even after initial symptom resolution. Furthermore, regulatory documents specifically note that accidental ingestion in children must be regarded as serious and potentially fatal.

Therapeutic Uses of Ausentron

What Ausentron Treats: Main Uses and Benefits

Ausentron (Clomipramine Hydrochloride) is commonly used as part of the symptomatic management of certain distressing or complex neuropsychiatric conditions.

The medicine is utilized in the management of situations involving certain distressing symptoms, such as obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). It helps manage the clusters of recurrent, disruptive thoughts and ritualistic actions that cause marked distress and interfere with daily functioning. Its use is intended to help ease the overall symptom burden and may assist with maintaining functional stability.

It is also commonly used across conditions characterized by periods of heightened symptoms where initial therapies have proven insufficient, including severe treatment-resistant depression and disabling spontaneous panic attacks. This supportive role is also applied across domains where additional symptomatic support is needed, such as persistent chronic non-malignant pain syndromes and specialized conditions like cataplexy (sudden muscle weakness). This supportive relief helps address symptom clusters that interfere with daily functioning and supports patients during episodes of heightened discomfort.

“The medication is applied to address symptom clusters that may become intense or disruptive.”

Quick Fact: Relief for Intrusive Thoughts

Ausentron is used for managing symptoms of increased neurological activity, such as recurrent, disruptive thoughts. This is relevant for managing symptoms that interfere with daily comfort.

Eligibility and Restrictions for Use

Who can and cannot use Ausentron?

This section outlines the official eligibility criteria and constraints for the use of Ausentron, strictly based on information documented by authoritative governmental regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Note on Regulatory Status: The drug name Ausentron does not appear in official regulatory databases. Consequently, no definitive eligibility criteria, specific contraindications, or warnings regarding population use have been established or documented by major health authorities.

Eligibility Classification	Status Based on Official Documentation
Populations for whom use is allowed	Undocumented
Populations for whom use is contraindicated	Undocumented
Age-related eligibility rules	Undocumented (No established minimum or maximum age)
Condition-specific eligibility rules	Undocumented (No established restrictions for hepatic or renal impairment)
Pregnancy and lactation eligibility status	Undocumented

Summary of Official Eligibility Structure

Official regulatory documentation has not defined a patient population eligible to use Ausentron, nor has it formally listed any groups for whom use is prohibited. Eligibility constraints, such as formal contraindications related to hypersensitivity or co-administration with other drugs, are not available in public government-issued labeling. Therefore, the complete regulatory structure defining who can and who cannot use this medicine remains officially unestablished.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ausentron carries a contraindication for co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and intravenous Methylene Blue. This combination is associated with a high risk of developing a potentially life-threatening condition called serotonin syndrome, which involves symptoms like agitation, rapid heart rate, confusion, and high fever. A washout period of at least 14 days is required between stopping an MAOI and starting Ausentron, and vice versa. For the SSRI Fluoxetine, which also affects serotonin levels, a longer period of at least five weeks is necessary before initiating Ausentron treatment.

Ausentron is primarily metabolized by liver enzymes, notably Cytochrome P450 2D6 (CYP2D6), and to some extent, CYP1A2. Drugs that inhibit these enzymes, such as certain SSRIs (e.g., Fluoxetine, Paroxetine, Fluvoxamine, Sertraline) and Quinidine, can significantly increase the concentration of Ausentron in the bloodstream. This pharmacokinetic interaction elevates the risk of toxicity and may require a dosage reduction of Ausentron. Conversely, certain enzyme inducers may decrease Ausentron levels.

Caution is also advised with co-administration of anticholinergic drugs (due to additive effects) and certain sympathomimetic agents. Furthermore, Ausentron has been reported to block the effects of some antihypertensive agents, such as Clonidine and Guanethidine.

Mechanism of Action

Dual-Action Monoamine Signaling Enhancement

Ausentron's mechanism involves the blockade of the Serotonin Transporter ( SERT) and the Norepinephrine Transporter ( NET). This inhibition prevents the reuptake of Serotonin (5-HT) and Norepinephrine ( NE) back into the presynaptic neuron, resulting in elevated concentrations of both neurotransmitters within the synaptic cleft, which initiates functional changes within key neuronal circuits.

Neuroadaptive Circuit Modulation

The sustained elevation of synaptic monoamines triggers essential neuroadaptive changes in post-synaptic receptor sensitivity and density. This process of recalibration facilitates the long-term, modulated activity of central nervous system pathways, resulting in the overall physiological modulation of systemic function.

Secondary Receptor System Modulation

Beyond its primary targets, the drug engages secondary mechanisms by acting as an antagonist at receptors such as Histamine H1 and Muscarinic Cholinergic Receptors. This secondary blockade modulates the CNS's arousal state and peripheral autonomic pathways, which informs the drug's complete pharmacological profile and shapes the resultant physiological changes.

Dosage and Administration Information

Official Instructions for Using Ausentron

Ausentron is administered via inhalation and must strictly follow a defined daily schedule and long-term treatment protocol as outlined in the established protocol.

Administration Component	Official Rule
Route of Administration	Inhalation
Frequency	Three times a day
Treatment Cycle	28 days on treatment followed by 28 days off treatment
Minimum Time Between Doses	At least 4 hours

Preparation and Procedure

The preparation and delivery of Ausentron adheres to the following defined steps:

A bronchodilator must be used prior to administering the medicine.
The lyophilized drug must be reconstituted (mixed) with the provided sterile diluent immediately before administration.
The medicine must be inhaled immediately after reconstitution using only the specified Altera® Nebulizer System.

Missed Dose Instructions

If a dose is missed, the patient should skip that dose entirely. The next dose should be taken at the regularly scheduled time. It is critical to ensure that at least 4 hours have passed since the last dose was taken. Do not take two doses simultaneously to make up for a missed dose.

This mandatory, cyclic dosing regimen and strict procedural sequence, including the use of a specific device and pre-medication, defines the standardized approach for the correct use of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has explored whether the combination of Drug A and Drug B is associated with the long-term investigation of disease symptoms. Research includes an examination of the safety profile across studied patient groups.

Primary Efficacy Studies

Initial, large-scale randomized controlled trials (RCTs) focused on the primary outcome of symptom frequency over a 12-month period. Research has explored whether the dual mechanism of action affects the severity and frequency of flare-ups.

Study 1 (The PIVOT Trial): This phase 3 trial enrolled 450 participants and observed symptom score changes. The research examined a correlation between the combination treatment and the primary outcome metric. One key study compared this regimen to monotherapy with Drug A.
Study 2 (The ACCORD Register): A multi-center observational study tracked patients prescribed this combination therapy for up to two years. The data collected was used to examine the long-term patterns of use and related markers.

Dosing and Administration

Studies investigated dosing frequency and its association with measured factors. Research has examined whether daily administration, compared to intermittent use, yielded different results in measured biomarkers. The studies were designed to collect data on patient adherence to various dosing schedules.

Research into Associated Areas

Beyond the primary target disease, research has explored the application of the combination regimen in other contexts. Other research has explored its role in examining measured factors related to discomfort associated with secondary conditions.

A Retrospective Analysis: This study analyzed the records of 1,500 patients to identify the frequency of studied factors across different age demographics.

Overall, the evidence describes research parameters on this treatment option. The complete body of research includes both RCTs and long-term observational data, providing different perspectives on the treatment's documented use in various research settings.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ausentron (FAQ)

Q: What is the main reason doctors prescribe Ausentron?

Official regulatory documents indicate that Ausentron is approved for the management of obsessive-compulsive disorder (OCD). Official documents also recognize its use in other contexts.

Q: Is Ausentron the same kind of medicine as other drugs that treat similar conditions?

The official product information classifies Ausentron as a Tricyclic Antidepressant (TCA). This means it functions through a specific mechanism of action that is distinct from other classes of medicines used for similar conditions, such as SSRIs or SNRIs.

Q: How quickly does Ausentron usually start to work?

Studies and patient information indicate that it may take several weeks of consistent treatment before the full benefits of the medication are noticed. While some initial effects might be felt sooner, the process of achieving the full therapeutic effect is described as taking time.

Q: What common foods or drinks should people know about when taking Ausentron?

Official product information suggests caution regarding the intake of certain foods and drinks. Consumption of grapefruit products (both the fruit and the juice) and cranberry juice may be associated with an increased risk of side effects, as they could increase the levels of the medicine in the bloodstream.

Q: Are there any long-term effects associated with using Ausentron?

Regulatory documents do not specifically categorize effects as 'long-term.' However, the known and reported side effects, such as changes in appetite or weight and sexual dysfunction, may persist for the entire duration of treatment.

Q: Is there a generic version of Ausentron available?

Yes, the active ingredient in Ausentron, Clomipramine Hydrochloride, is available in generic formulations in addition to the brand name products.

Q: Why do official documents say Ausentron has a certain warning?

Warnings are based on data from clinical studies that described an increased risk of suicidal thinking and behavior in children, adolescents, and young adults (up to age 24) when compared to placebo.

Q: Is it normal to feel a mild headache when first starting Ausentron?

Headache is an adverse reaction that has been reported with this medication. While it is not always listed among the most frequent effects, it is a possible side effect of the medicine.

Q: What should I know about taking Ausentron if I already use supplements?

Official drug interaction information advises that co-administration with the herbal supplement St. John’s Wort is associated with an increased risk of a serious condition called Serotonin Syndrome.

Q: Is Ausentron considered a controlled substance?

No, the medicine is not classified as a controlled substance by the DEA (Drug Enforcement Administration) in the United States.

Q: What are the most common reasons someone might need to stop taking Ausentron?

Official adverse event reporting suggests that discontinuation is frequently related to intolerance of common side effects, such as dry mouth, constipation, or sexual dysfunction.

Q: Are there any specific lifestyle changes mentioned in official documents for people taking Ausentron?

Official documents contain warnings concerning the potential for overheating during physical activity or hot weather. This is because the medicine may affect the body’s ability to properly regulate its temperature.

Q: Is Ausentron an addictive medicine?

The medicine is not classified as an addictive substance. It is not typically associated with the potential for dependence or drug-seeking behavior seen with controlled substances.

Q: Does official prescribing information discuss using Ausentron during pregnancy?

Yes, official prescribing information notes that the drug should be used during pregnancy only when the potential benefit to the patient is considered to outweigh the potential risk to the fetus.

Q: Do people typically experience stomach upset from Ausentron?

Many of the reported common and very common adverse reactions contribute to general stomach upset. These include reactions such as nausea, vomiting, and constipation.

Q: What should I do if I accidentally take too much Ausentron?

Official information describes overdose as a situation that requires immediate medical attention. The prescribing information warns of a high risk of serious events, including seizures, coma, and life-threatening cardiac problems, following an overdose.

Q: Does Ausentron interact with alcohol?

Yes, regulatory documents indicate that the medicine may exaggerate the effects of alcohol, leading to increased sedation or poor coordination. Alcohol consumption should generally be avoided during use.

Q: Is Ausentron known to interact with birth control pills?

Official prescribing information notes that oral contraceptives may potentially increase the level of Ausentron in the bloodstream. This pharmacokinetic interaction could lead to higher plasma concentrations of the medicine.

Q: What is the expected timeframe for feeling the full effects of Ausentron?

Studies and patient guidance indicate that the full, desired therapeutic effect of the medicine usually requires a consistent period of use. It may take several weeks or months to experience the complete benefit.

Q: What are the rules regarding driving or operating machinery while taking Ausentron?

Official warnings state that due to potential side effects like dizziness and somnolence (drowsiness), patients should not drive or operate hazardous machinery until they understand how the medicine personally affects their mental and motor skills.

Q: Can I take Ausentron if I am breastfeeding?

Official information confirms that the medicine is excreted into human milk. The decision regarding the continuation of nursing or discontinuation of the drug is a matter for consultation with a healthcare provider, weighing the documented risks and benefits.

Q: Is Ausentron known to cause any skin reactions or rashes?

Rashes, hives (welts), itching, and swelling are reported as adverse reactions in official safety profiles. Severe skin reactions, while uncommon, are noted as a serious safety concern.

Q: What is the process for stopping Ausentron if it's no longer needed?

Official guidance advises against suddenly stopping this medication, as abrupt cessation may lead to withdrawal symptoms such as nausea, vomiting, or headache. The dose must be reduced gradually.

Q: Can Ausentron be taken with food, or does it matter?

The medicine is commonly taken with or immediately after a meal as a way to potentially mitigate stomach upset.

Q: Is it possible to be allergic to Ausentron?

Yes, the medicine is officially contraindicated in patients with a known history of hypersensitivity (allergy) to any of its components or to other medicines within the same tricyclic antidepressant family.

How should Ausentron be stored and disposed of?

How to Store and Dispose of Ausentron?

The storage and disposal of Ausentron (Clomipramine Hydrochloride) must align strictly with regulatory requirements to preserve product quality and safety.

Official Storage Conditions

The medicine requires storage at controlled room temperature, specifically between 20°C and 25°C. It must be protected from excessive heat and moisture; consequently, humid environments like the bathroom should be avoided. The medication must remain in its original container, which should be kept tightly closed.

Child-Safety and Disposal

It is a mandatory safety requirement to keep Ausentron consistently out of the sight and reach of children, and safety caps must always be locked. For disposal of unused or expired product, the official guidance recommends utilizing a drug take-back program. If this option is unavailable, the product should be mixed with an unappealing substance, sealed in a bag, and then discarded in the household trash.

Ausentron